Mike Kratky, CFA

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Research
Mike Kratky, CFA

Mike Kratky, CFA is as a Senior Research Analyst at Leerink Partners, specializing in the coverage of Medical Devices and Technology.

Mike initially joined the Firm in 2018 as an Associate focused on the immunology and inflammation space. Recognized for his exceptional contributions, he was promoted to Vice President before leaving the Firm in March 2020. Subsequently, Mike gained valuable experience during his one-year tenure at Verition Fund Management and later rejoined Leerink Partners in March 2021. Prior to his time at Leerink Partners, he held various roles at B. Riley FBR, Nasdaq, and MKM Partners.

Mike earned his B.A. in Economics from Colgate University and holds the Chartered Financial Analyst designation.

Partner With Us

Contact Us